Evaluation of a brain-targeting zidovudine chemical delivery system in dogs

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 1, 1997, Pages 122-128

  Brewster, Marcus E ^a,b,c   Anderson, Wesley R ^a,b,c   Webb, Alistair I ^d   Pablo, Luisito M ^d   Meinsma, Donald ^a,b   Moreno, Dan ^a,b   Derendorf, Hartmut ^c   Bodor, Nicholas ^c   Pop, Emil ^a,b,c  

^a Pharmos Corporation   (United States)

^b Kiryat Weizmann   (Israel)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' (1 METHYL 1,4 DIHYDROPYRIDIN 3 YL) 3' AZIDO 3' DEOXYTHYMIDINE; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE DERIVATIVE; ZIDOVUDINE N METHYLNICOTINIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN INFECTION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG TARGETING; DRUG UPTAKE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031033508     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.1.122     Document Type: Article

References (47)

1. Aggarwal, S., S. Gogu, S. Rangan, and K. Agarwal. 1990. Synthesis and biological evaluation of prodrugs of zidovudine. J. Med. Chem. 33:1505-1510.
2. Amselem, S., D. Friedman, A. Yogev, W. Anderson, D. Helton, N. Bodor, E. Pop, and M. E. Brewster. 1995. Formulation development for a zidovudine chemical delivery system. 2. Towards oral and non-parenteral dosage forms. Int. J. Pharm. 125:31-43.
3. Bodor, N., H. Farag, and M. Brewster. 1981. Site-specific, sustained release of drugs to the brain. Science 214:1370-1372.
4. Bodor, N., and M. Brewster. 1991. Chemical delivery systems, p. 231-284. In R. Juliano (ed.), Handbook of experimental pharmacology, vol. 100. Targeted drug delivery. Springer-Verlag, Berlin, Germany.
5. Bodor, N., and M. Brewster. 1983. Problems of delivery of drugs to the brain. Pharmacol. Ther. 19:337-386.
6. Brew, J., M. Rosenblum, and R. Price. 1988. AIDS dementia complex and primary brain infection. J. Neuroimmunol. 20:133-140.
7. Brewster, M., K. Estes, T. Loftsson, R. Perchalski, H. Derendorf, G. Mullersman, and N. Bodor. 1988. Improved delivery through biological membranes. XXXI. Solubilization and stabilization of an estradiol chemical delivery system by modified β-cyclodextrins. J. Pharm. Sci. 77:981-985.
8. Brewster, M., K. Estes, and N. Bodor. 1990. An intravenous toxicity study of 2-hydroxypropyl-β-cyclodextrin, a useful drug solubilizer, in rats and monkeys. Int. J. Pharm. 59:231-243.
9. Brewster, M., W. Anderson, and N. Bodor. 1991. Brain, blood and cerebrospinal fluid distribution of a zidovudine chemical delivery system in rabbits. J. Pharm. Sci. 80:843-846.
10. Brewster, M. 1991. Parenteral safety and applications of 2-hydroxypropyl-β-cyclodextrin, p. 313-350. In D. Duchene (ed.), New trends in cyclodextrins. Editions de Sante Publishers, Paris, France.
11. Brewster, M., and N. Bodor. 1992. Redox approaches to drug delivery to the central nervous system. NIDA Res. Monogr. 120:169-201.
12. Brewster, M., E. Pop, and N. Bodor. 1993. Chemical approaches to brain-targeting of biologically active compounds, p. 453-467. In A. Kozikowski (ed.). Drug design for neurosciences. Raven Press, New York, N.Y.
13. Brewster, M., E. Pop, A. Braunstein, A. Pop, P. Druzgala, A. Dinculescu, W. Anderson, A. El Koussi, and N. Bodor. 1993. The effect of dihydronicotinate N-substitution on the brain-targeting efficacy of a zidovudine chemical delivery system. Pharm. Res. 9:1356-1362.
14. Brewster, M., T. Loftsson, S. Amselem, D. Friedman, A. Yogev, W. Anderson, D. Helton, A. Dinculescu, N. Bodor, and E. Pop. 1995. Formulation development for a zidovudine chemical delivery system. 1. Parenteral dosage forms. Int. J. Pharm. 125:17-30.
15. Brewster, M., W. R. Anderson, D. Helton, N. Bodor, and E. Pop. 1995. Dose-dependent brain delivery of zidovudine through the use of a zidovudine chemical delivery system. Pharm. Res. 12:796-798.
16. Brewster, M. E., K. Raghavan, E. Pop, and N. Bodor. 1994. Enhanced delivery of ganciclovir to the brain through the use of redox targeting. Antimicrob. Agents Chemother. 38:817-823.
17. Bridge, T., and L. Ingraham. 1990. Central nervous system effects of human immunodeficiency virus type 1. Annu. Rev. Med. 41:159-168.
18. Brinchmann, J., F. Vartdal, and E. Thorsby. 1989. T-Lymphocyte subset changes in human immunodeficiency virus infection. J. Acquired Immune Defic. Syndr. 2:398-403.
19. Chu, C., V. Bhadti, K. Doshi, J. Etse, J. Gallo, F. Boudinot, and R. Schinazi. 1990. Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido-3′-deoxythymidine. J. Med. Chem. 33:2188-2192.
20. DeClercq, E. 1987. Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). J. Med. Chem. 29:1561-1569.
21. Dykstra, K., A. Arya, D. Arriola, P. Bungay, P. Morrison, and R. Dedrick. 1993. Microdialysis study of zidovudine (AZT) transport in brain. J. Pharmacol. Exp. Ther. 267:1227-1236.
22. Gallo, J., Y. Sanzgiri, E. Howerth, T. Finco, J. Wilson, J. Johnston, R. Tackett, and S. Budsberg. 1992. Serum, cerebrospinal fluid and brain concentrations of a new zidovudine formulation following chronic administration via an implantable pump in dogs. J. Pharm. Sci. 81:11-15.
23. Gallo, J., J. Etse, K. Doshi, F. Boudinot, and C. Chu. 1991. Hybrid pharmacokinetic models to describe anti-HIV nucleoside brain disposition following parent and prodrug administration in mice. Pharm. Res. 8:247-253.
24. Glasner, P., and R. Kaslow. 1990. The epidemiology of human immunodeficiency virus infection. J. Consult. Clin. Psychol. 58:13-21.
25. Gogu, S., S. Aggarwal, S. Rangan, and K. Agrawal. 1989. A pro-drug of zidovudine with enhanced efficacy against human immunodeficiency virus. Biochem. Biophys. Res. Commun. 160:656-661.
26. Good, S. S., D. Durack, and P. de Miranda. 1986. Biotransformation in various species and in humans of 3′-azido-3′-deoxythymidine, a potential agent for the treatment of AIDS. Fed. Proc. 45:444.
27. Grant, I., and R. Heaton. 1990. Human immunodeficiency virus type 1 (HIV-1) and the brain. J. Consult. Clin. Psychol. 58:22-30.
28. Hollander, H. 1991. Neurological and psychiatric manifestations of HIV disease. J. Gen. Intern. Med. 6(Suppl):S24-S31.
29. Kline, M., and W. Shearer. 1991. Impact of human immunodeficiency virus infection on women and infants. Infect. Dis. Clin. N. Am. 6:1-17.
30. Krasny, H. C., and S. S. Good. 1986. Pharmacokinetics and metabolism of azidothymidine in the dog. Fed. Proc. 46:207.
31. Little, R., D. Bailey, M. Brewster, K. Estes, R. Clemmons, A. Saab, and N. Bodor. 1990. Improved delivery through biological membranes. XXXIII. Brain-enhanced delivery of azidothymidine (AZT). J. Biopharm. Sci. 1:1-18.
32. Lupia, R., N. Ferencz, J. Lertora, S. Aggarwal, W. George, and K. Agrawal. 1993. Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. Antimicrob. Agents Chemother. 37:818-824.
33. Masereeuw, R., U. Jaehde, M. Landemeijer, A. de Boer, and D. Breimer. 1994. In vitro and in vivo transport of zidovudine (AZT) across the bloodbrain barrier and the effects of transport inhibitors. Pharm. Res. 11:324-330.
34. Mizrachi, Y., A. Rubinstein, Z. Harish, A. Biegon, W. Anderson, and M. Brewster. 1995. Improved brain delivery and in vitro activity of zidovudine (AZT) through the use of a redox chemical delivery system. AIDS 9:153-158.
35. Neuwelt, E. 1989. Implications of the blood-brain barrier in physiology and medicine. Plenum Press, New York, N.Y.
36. Pajeau, A., and G. Roman. 1992. HIV encephalopathy and dementia. Psychiatr. Clin. N. Am. 15:455-466.
37. Purdy, B., and K. Plaisance. 1989. Infection with human immunodeficiency virus: epidemiology, pathogenesis, transmission, diagnosis and manifestations. Am. J. Hosp. Pharm. 46:1185-1209.
38. Rapoport, S. 1976. The blood-brain barrier in physiology and medicine. Raven Press, New York, N.Y.
39. Reinvang, I., S. Froland, and V. Skripeland. 1991. Prevalence of neuropsychological deficit in HIV. Acta Neurol. Scand. 83:289-293.
40. Sawchuk, R., and M. Hedaya. 1990. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effects of prohenecid. Pharm. Res. 7:332-338.
41. Terasaki, T., and W. Pardridge. 1988. Restricted transport of 3′-azido-3′-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J. Infect. Dis. 158:630-632.
42. Tuntland, T., R. Ravasco, S. Al-Habet, and J. Unadkat. 1994. Efflux of zidovudine and 2′,3′-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. Pharm. Res. 11:312-317.
43. Weber, J. 1989. The biology and epidemiology of HIV infection. J. Antimicrob. Chemother. 23(Suppl. A):1-7.
44. Wong, S., K. van Belle, and R. Sawchuk. 1993. Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit. Investigation of the inhibitory effect of probenicid utilizing microdialysis. J. Pharmacol. Exp. Ther. 264:899-909.
45. Wong, S., M. Hedaya, and R. Sawchuk. 1992. Competitive inhibition of zidovudine clearance by probenicid during continuous coadministration. Pharm. Res. 9:228-235.
46. Yarchoan, R., R. Klecker, K. Weinhold, P. Markham, H. Lyerly, D. Durack, E. Gelmann, S. Lehrman, R. Blum, D. Barry, G. Shearman, M. Fischl, H. Mitsuta, R. Gallo, J. Collins, D. Bolognesi, C. Myers, and S. Broder. 1986. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/ LAV replication, to patients with AIDS or AIDS-related complex. Lancet i:575-580.
47. Yarchoan, R., G. Berg, P. Brouwers, M. Fischl, A. Spitzer, A. Wichman, J. Grafman, R. Thomas, B. Safai, A. Brunetti, C. Perno, P. Schmist, S. Larson, C. Myers, and S. Broder. 1987. Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet i:132-135.